NCT02090959: A reported trial by PTC Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02090959 |
|---|---|
| Title | A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 20, 2014 |
| Completion date | June 12, 2018 |
| Required reporting date | June 12, 2021, midnight |
| Actual reporting date | July 17, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |